CombinatoRx Incorporated has discontinued CRx-140 as an oral, systemic product candidate for psoriasis after preliminary results of the phase 2 clinical trial did not demonstrate desired results.
CRx-140 in patients failed to achieve statistical significance of the primary and secondary efficacy endpoints of reduction in PGA and PASI versus active control. These results, taken within the context of the CombinatoRx portfolio of product candidates, are not supportive of further clinical evaluation of CRx-140, states the company release.
"CRx-140 was one of a portfolio of seven product candidates that CombinatoRx is currently testing in phase 2 clinical trials and we look forward to reporting data from these trials throughout the year," said Alexis Borisy, president and CEO of CombinatoRx.
CombinatoRx Incorporated is a biopharmaceutical company focused on developing new medicines built from synergistic combinations of approved drugs, designed to attack disease on multiple fronts. CombinatoRx applies its proprietary combination drug discovery technology to identify new combination product candidates in a number of disease areas, including immuno-inflammatory disease, oncology, metabolic disease, neurodegenerative disease, and infectious disease.